Menu
Curie Logo
Donate
  • Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Prostate cancer
    Paris
    PRESTO (GETUG-AFU 36)
    Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial

    GILLES CREHANGE

  • Digestive cancers
    Paris, Saint-Cloud
    ProActIF-01
    ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers

    TIMOTHEE MARCHAL

  • Lung cancer
    Paris, Saint-Cloud
    REAL MOOV LUNG
    Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

    NICOLAS GIRARD

  • Lung cancer
    Paris
    RMC-LUNG-101
    Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors

    PAULINE DU RUSQUEC

  • Breast cancer
    Paris, Saint-Cloud
    ROMANCE (RAD05-UC-0107/1803)
    Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast

  • Childhood and adolescent cancers
    Paris
    SIOP EPENDYMOMA II
    An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma

    FRANCOIS DOZ

  • Breast cancer
    Paris, Saint-Cloud
    SKYLINE
    Tiragolumab, atezolizumab and chemotherapy in triple negative breast cancer:;A phase II trial.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    TAS6417-301
    Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.

    NICOLAS GIRARD

  • Prostate cancer
    Paris, Saint-Cloud
    TEMPOS (GETUG P14)
    Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy

    GILLES CREHANGE

  • Breast cancer
    Paris
    TRANS ROSALEE
    A BIOMARKER-DIRECTED, TRANSLATIONAL STUDY OF HIGH-THROUGHPUT MOLECULAR PROFILING OF HR+/HER2- METASTATIC BREAST CANCER TREATED WITH ENDOCRINE THERAPY AND RIBOCICLIB.

    HELENE SALAUN

  • Paris, Saint-Cloud
    TUMOSPEC (ONCO04) - Paris
    Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

    DOMINIQUE STOPPA-LYONNET

  • Childhood and adolescent cancers
    Paris
    iMATRIX-Alectinib (GO42286)
    A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.

    FRANCOIS DOZ

  • Breast cancer
    Paris, Saint-Cloud
    TOPOLOGY
    A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

    FRANCOIS-CLEMENT BIDARD

  • Cancers gynécologiques
    Paris
    GLORIOSA
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).

    MANUEL RODRIGUES

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • Lung cancer
    Paris
    DS1062-A-U303/ TROPION-Lung07
    A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)

    NICOLAS GIRARD

  • Eye tumors / Uveal melanoma
    Paris
    IDE 196-002
    IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator·s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).

    SOPHIE PIPERNO-NEUMANN

  • Paris, Saint-Cloud
    POP-ART
    A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.

    FRANCOIS-CLEMENT BIDARD

  • Paris
    EGL-001 (EGL-121)
    First-in-human Trial of EGL-001 in Patients with Selected Advanced And/·or Metastatic Solid Tumors

    EDITH BORCOMAN

  • Paris
    DF6215-001
    A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

    EMANUELA ROMANO

  • Lung cancer
    Paris
    MK-2870-004
    A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.

    CATHERINE DANIEL

  • Lung cancer
    Paris
    BAYER 22615 (SOHO 02)
    A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.

    NICOLAS GIRARD

  • Paris
    EUonQoL
    Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.

  • Lung cancer
    Paris
    HARMONi-3
    A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

    PAULINE DU RUSQUEC

  • Paris, Saint-Cloud
    PALLU
    A randomized comparative prospective multicenter study of the efficacy of a systematic referral to palliative care of patients who need for palliative care during an unscheduled visit in comprehensive anticancer centers.

    CAROLE BOULEUC-PARROT

  • Paris
    MK3475-522 (Keynote-522)
    A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    MARIE PAULE SABLIN

  • Childhood and adolescent cancers
    Paris
    I3Y-MC-JPEH
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    ISABELLE AERTS GAJDOS

  • Sarcomas
    Paris
    TRUST
    Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

    CLEMENT BONNET

  • Sarcomas
    Paris
    TANGENT (SNX-301-020)
    A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

    SOPHIE PIPERNO-NEUMANN

  • Lung cancer
    Paris
    R2810-ONC-2268
    A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075

    NICOLAS GIRARD

<
1 2...7
>